The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaPharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaThe role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapyRole of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacologyMATE1 regulates cellular uptake and sensitivity to imatinib in CML patientsPharmGKB summary: very important pharmacogene information for SLC22A1In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatmentThe Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients.Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeuticsCellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins.OCT1 and imatinib transport in CML: is it clinically relevant?Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children.Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemia.Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.Gene expression patterns as predictive biomarkers in hematology-oncology: principal hurdles on the road to the clinic.Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia PatientsHow is the relationship between TWIST-1 and BCR-ABL1 gene expressions in Chronic Myeloid Leukemia Patients?Fine Mapping and Functional Analysis Reveal a Role of SLC22A1 in Acylcarnitine Transport.Connections between pharmacoepidemiology and cancer biology: designing biologically relevant studies of cancer outcomes.Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemiaPolymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients
P2860
Q26749324-7F095C84-A45E-4341-A067-20A1B8F2ACFCQ26781539-EE979DFE-05F4-433B-8A1D-B0A6AEAABC71Q26830005-CEDE393F-A998-485E-810B-BF04281828C3Q27026858-26220EEA-A991-40D0-9938-73303FFBFD9FQ30313870-9AD9BD80-7407-477F-9B52-7EB4DE8F2C88Q33671763-8A445347-DA22-4A4C-9FA4-53AA0E2B734DQ35819214-DC9E60AD-F975-4A0F-B876-2500990ADFD0Q35922779-820ABCCF-E00A-426B-9223-C44A5F5F521EQ36610479-C62715AD-59EC-4591-A85E-14294730D568Q37285542-C0793AEB-0780-4C72-82D5-E2769D35B28CQ37598626-30479C07-27D8-4576-9C73-89914DFF522BQ38222511-9399A20B-5454-47C8-BB1C-FB7DE65B359DQ38540022-5520ED57-AF57-4816-8E47-FB800F4F4039Q38622785-528BF327-2D82-4890-84F7-E1F220A139CDQ38805917-88799AC2-32B1-4257-B1C5-910097F9ED14Q38826494-77C553B1-4BC0-4499-A7FE-B73470368DC6Q38843265-A13300E4-9FA7-4F5B-BE21-27DBB72E9ED4Q38888369-51C4E8E2-E8B4-4FA7-86D9-A18250319D31Q38902116-C8D08652-B007-439B-B990-E441BECA6D5FQ38959826-6A7E93D4-089D-4763-B1CA-8B3E0F494FF3Q40721053-DDD3DF30-7C43-402C-805B-2FBBEDFF7289Q42334352-BE9CC352-927B-4BCF-B241-697DD0CE853BQ47117554-3D881EEF-072F-43A6-BAB7-83F823D3D615Q47235766-8A2AE93A-0AED-4D66-856C-1AEDBE4E195EQ47752654-3053050E-4E1E-4236-B93A-FECD68F5F51AQ49257885-707F5DCF-593D-4544-A68A-4F223197C837Q49833785-EC9FE000-47A0-497C-BD0E-0D5DF4AA88A5Q54222903-9F01AD03-1D5C-4075-B214-0CFA7436E9A2Q54240000-E6397169-0083-48D2-BA36-21FC7DFCA1AAQ56973578-25363615-9C71-429D-AFC5-CFEB80BA816FQ58765353-C56E02C5-5EBC-46F3-99D1-F122C06E43B3
P2860
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The hOCT1 SNPs M420del and M40 ...... ated chronic myeloid leukemia.
@en
The hOCT1 SNPs M420del and M40 ...... ated chronic myeloid leukemia.
@nl
type
label
The hOCT1 SNPs M420del and M40 ...... ated chronic myeloid leukemia.
@en
The hOCT1 SNPs M420del and M40 ...... ated chronic myeloid leukemia.
@nl
prefLabel
The hOCT1 SNPs M420del and M40 ...... ated chronic myeloid leukemia.
@en
The hOCT1 SNPs M420del and M40 ...... ated chronic myeloid leukemia.
@nl
P2093
P50
P1433
P1476
The hOCT1 SNPs M420del and M40 ...... ated chronic myeloid leukemia.
@en
P2093
Andrea Davies
Andrea L Jorgensen
Gemma Austin
Jieying-Eunice Zhang
Letizia Foroni
Lihui Wang
Martin C Müller
Panagiotis D Kottaridis
Richard E Clark
Sudeep Pushpakom
P304
P356
10.1182/BLOOD-2012-01-405035
P407
P577
2012-12-05T00:00:00Z